Livzon Pharmaceutical Group Inc Class H (LVZPF)
OTHER OTC:LVZPF
LVZPF Stock Chart & Stats
$5.22
-$0.09(-2.56%)
At close: 4:00 PM EST
$5.22
-$0.09(-2.56%)
Day’s Range― - ―
52-Week Range$2.72 - $5.40
Previous CloseN/A
Volume1.19K
Average Volume (3M)3.00
Market Cap
$4.05B
Enterprise Value$25.11B
Total Cash (Recent Filing)$10.93B
Total Debt (Recent Filing)$3.85B
Price to Earnings (P/E)11.6
Beta0.29
Next Earnings
Apr 24, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield3.44%
Share Statistics
EPS (TTM)0.04
Shares Outstanding299,807,130
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-8.67
Price to Book (P/B)1.65
Price to Sales (P/S)1.97
P/FCF Ratio9.02
Enterprise Value/Market Cap6.19
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda8.27
Forecast
1Y Price Target
$2.93Price Target Upside-43.82% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.3
Revenue Forecast (FY)$1.54B
Bulls Say, Bears Say
Bulls Say
Sustained ProfitabilityHigh gross and operating margins with mid-teens ROE indicate durable pricing power and operational efficiency. Over a 2–6 month horizon these fundamentals support sustained cash generation, margin resilience against cyclical swings, and capacity to fund R&D or product launches.
Robust Free Cash FlowFree cash flow roughly matching net income signifies current earnings quality and the firm's ability to internally fund operations, capex, and distributions. This reliable cash generation supports strategic flexibility and reduces near-term financing reliance over coming months.
Vertical Integration / Manufacturing CapabilityControl across finished drugs and selected upstream APIs gives structural supply-chain advantages: cost control, margin protection, and faster commercialization. This integration supports competitive resilience and steadier production access over the medium term.
Bears Say
Stagnant Revenue TrendFlat to modestly declining revenues reduce growth optionality and raise reliance on margin improvements or cost cuts to drive earnings. Without clear product or market expansion, stagnant top-line limits durable earnings growth and constrains long-term reinvestment capacity.
Margin CompressionA notable fall in EBITDA margin signals rising cost pressures or adverse mix shift. If persistent, margin erosion reduces operating leverage, weakens cash flow cushion, and forces tougher trade-offs between pricing, volume, and investment over the next several quarters.
Inconsistent Cash ConversionHistorical variability in converting profits to cash and a low operating cash coverage ratio imply earnings may not reliably translate into liquidity. This raises execution risk for funding dividends, capex, or acquisitions without tapping external financing in adverse periods.
Livzon Pharmaceutical Group News
LVZPF FAQ
What was Livzon Pharmaceutical Group Inc Class H’s price range in the past 12 months?
Livzon Pharmaceutical Group Inc Class H lowest stock price was $2.72 and its highest was $5.40 in the past 12 months.
What is Livzon Pharmaceutical Group Inc Class H’s market cap?
Livzon Pharmaceutical Group Inc Class H’s market cap is $4.05B.
When is Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date?
Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date is Apr 24, 2026 which is in 17 days.
How were Livzon Pharmaceutical Group Inc Class H’s earnings last quarter?
Livzon Pharmaceutical Group Inc Class H released its earnings results on Mar 24, 2026. The company reported $0.044 earnings per share for the quarter, missing the consensus estimate of $0.054 by -$0.01.
Is Livzon Pharmaceutical Group Inc Class H overvalued?
According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Overvalued.
Does Livzon Pharmaceutical Group Inc Class H pay dividends?
Livzon Pharmaceutical Group Inc Class H pays a Annually dividend of $0.153 which represents an annual dividend yield of 3.44%. See more information on Livzon Pharmaceutical Group Inc Class H dividends here
What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?
Livzon Pharmaceutical Group Inc Class H’s EPS estimate is 0.1.
How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?
Livzon Pharmaceutical Group Inc Class H has 299,807,130 shares outstanding.
What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?
Livzon Pharmaceutical Group Inc Class H reported an EPS of $0.044 in its last earnings report, missing expectations of $0.054. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?
Currently, no hedge funds are holding shares in LVZPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Livzon Pharmaceutical Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.39%
12-Months-Change
Fundamentals
Return on Equity
14.47%
Trailing 12-Months
Asset Growth
2.44%
Trailing 12-Months
Company Description
Livzon Pharmaceutical Group Inc Class H
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
LVZPF Stock 12 Month Forecast
Average Price Target
$2.93
▼(-43.82% Downside)
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
3.19% Mutual Funds
― Other Institutional Investors
94.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---